top of page
Nephrospec Treatment CURESPEC LOGO ON W_edited.jpg
Curespec logo 1.png
About Us


The Global CKD and Hypertension Pandemic affects 1.13 Billion people worldwide, inflicting death and suffering. 
Global healthcare costs are estimated at over $500 Billion (1) a year.

Hypertension is one of the main causes of CKD - costing Medicare, in the USA alone,
over $84 billion (2,3) a year.

The only current solution, Dialysis, dramatically reduces patients' quality-of-life

 – 5-year patient survival probability for all renal replacement therapy - 50.8% (4).

CureSpec was Founded in 2020.
Our first market-ready product, Nephrospec™ is intended for the interrelated treatment of: 

- CKD (Chronic Kidney Disease)

- Hypertension (High Blood Pressure)

NephroSpec - Saving lives & costs

NephroSpec promotes new blood vessel formation and restores damaged tissue

function by means of its patented ShockWave technology. 

We hold an Established, market-ready product, with a strong IP portfolio, which includes a granted U.S. patent,

a fully developed CE-Marked device & Promising preliminary clinical results.


CureSpec has an established Production facility, a Global distribution chain and an experienced management team. 



  3. Gaziano TA, Asaf B, S Anand, The global cost of non-optimal blood pressure. J  Hypertens. 2009

  4. Kramer A, Boenink R, Noordzij M, et al. The ERA-EDTA Registry Annual Report 2017 : a summary. 2020

Our Product

Nephrospec    - a medical device manufactured by Curespec.

Nephrospec    - a safe, non-invasive shockwave device intended for the treatment of CKD and Hypertension

Nephrospec    - promotes new blood vessel formation and restores damaged tissue function through its patented technology

Nephrospec    - saves up to 80% of costs while easing suffering and needless loss of lives

Benefits include:

  • Complementary solution to optimal medical care for CKD and hypertension

  • Kidney function improvement in weeks

  • Outpatient treatment delays onset of dialysis







Pre treatment

ARAS Kidney


Post Shockwave treatment

Curespec uses shockwave technology to produce a neovascularization affect on the kidneys.


Our Team

Our Team

Avner Spector_edited.jpg

Avner Spector

Founder, Active Chairman

Mr. Spector has over 30 years experience in the international Medtech industry, having held top R&D management positions in medical instrument companies in Israel and the US. He holds a B.Sc. Degree in Mechanical Engineering from Ben-Gurion-University of the Negev, Israel.

  • Grey LinkedIn Icon
rotem k_edited.jpg

Rotem Kaynan


Mr. Kaynan is a Biomedical Engineer, 2005 Technion – Israel Institute of Technology. More than 15 years of experience in Medical Devices, leading teams of clinical applications, sales & product management.

  • Grey LinkedIn Icon

Ophir Brandt


Mr. Brandt is a Certified Public Accountant (CPA) from the Bar-Ilan University, and holds an MBA degree from the Hebrew University. Mr. Brandt has over 10 years of experience in financial management, including as a CFO in the private sector and as a Senior Auditor at Ernst & Young (EY). 

  • Grey LinkedIn Icon

Alex Slutzker

VP Clinical, Cofounder

Dr. Slutzker (Ph.D) has 10 years of experience in the clinical diagnostics and medical device fields. He holds a doctorate in the fields of Molecular biology, biochemistry and microbiology from the Ben-Gurion-University of the Negev, Israel

  • Grey LinkedIn Icon

Hagay Spector

R&D Director

Mr. Spector is an Electronics Engineer, (from 2009, HIT- Holon Institute of Technology). His major expertise is Product Development in all of its layers with wide knowledge in Shockwave systems and X-ray Vision. 

  • Grey LinkedIn Icon
yael shpilman.jpg

Yael Spielmann

RA Manager

Yael Spielmann has over 17 years of experience in the medical device industry, serving as a Regulatory Affairs expert, developing regulatory strategies and compiling submissions to regulatory bodies worldwide.

  • Grey LinkedIn Icon

Advisory Board


Lilach O. Lerman, MD, PhD

The Arthur M. and Gladys D. Gray Professor in Honor of Dr. Howard A. Andersen Professor of Medicine and Physiology Director, Reno- Vascular Research Laboratory Division of Nephrology and Hypertension Mayo Clinic

  • Grey LinkedIn Icon

Amir Lerman, M.D.

Barbara Woodward Lips Professor 

Associate Chair, Cardiovascular  Medicine Director - Cardiovascular Research Center Consultant, Department of Cardiovascular Medicine Mayo Clinic

  • Grey LinkedIn Icon
Contact Us

Contact Us

Thanks for submitting!

  • Instagram
  • Facebook
  • LinkedIn
bottom of page